Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14313963 | 0.99 | P2RX3 (0.49) | P2RX3P2RX1P2RX2P2RX4PRMT5 | |
| SCHEMBL14313960 | 0.93 | PRMT5 (0.48) | PRMT5WDR77P2RY1P2RY2SRC | |
| SCHEMBL23584298 | 0.84 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL16024812 | 0.84 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL16203364 | 0.84 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL19774632 | 0.84 | PRMT5 (0.40) | PRMT5WDR77RNASELADK | |
| SCHEMBL20324592 | 0.82 | ADK (0.50) | PRMT5WDR77P2RY1P2RY2SRC | |
| SCHEMBL18844368 | 0.81 | P2RX3 (0.47) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL20059185 | 0.81 | P2RX1 (0.59) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL30558659 | 0.80 | P2RY1 (0.66) | P2RX3P2RX1P2RX2P2RX4P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | P2RX3 1693/4885P2RX1 1675/4885P2RX2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.